ValiRx plc
VAL.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.07 | 0.04 | 0.31 |
| FCF Yield | 0.00% | -69.30% | -22.07% | -11.11% |
| EV / EBITDA | 0.00 | 0.57 | -3.64 | -5.82 |
| Quality | ||||
| ROIC | 0.00% | -25.66% | -29.36% | -36.31% |
| Gross Margin | 0.00% | -166.82% | 0.00% | -1,331.49% |
| Cash Conversion Ratio | 0.74 | 0.91 | 0.67 | 1.07 |
| Growth | ||||
| Revenue 3-Year CAGR | 390,022.69% | 212,431.71% | 212,431.71% | -100.00% |
| Free Cash Flow Growth | 0.00% | 22.05% | -35.97% | 52.35% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 1.69 | 0.86 | 0.15 |
| Interest Coverage | 0.00 | -1,051.04 | -4,387.29 | -336.03 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 1.92 | 1.94 | 0.00 |
| Cash Conversion Cycle | 0.00 | 131.28 | 46.28 | -81.63 |